Zdrowie i gospodarka · 13.10.2017
"Determining Whether To Submit an Abbreviated New Drug Application or a 505(b)(2) Application;" Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Determining Whether to Submit an ANDA or a 505(b)(2) Application." This guidance is intended to serve as a foundational guidance to assist applicants in determining which one of the abbreviated approval pathways under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) is appropriate for the submission of a marketing application to FDA.